DMAA
Drugs Made In America Acquisition Corp.
NASDAQ · Financial Services · Shell Companies · US
$10.87
+0.09%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -99.8%
- Free cash flow
- +47.0%
- Operating cash flow
- +47.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +439.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026